Generated by AI
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases. Its current portfolio centers on therapeutic biologics designed to selectively modulate disease-specific T cells and restore immune balance without broad immune suppression. The company’s lead asset, CUE-221, is an anti-IgE antibody being advanced for allergic diseases, while CUE-401 is a bifunctional IL-2 and TGF-β program designed to support Treg-mediated tolerance in autoimmune conditions. Cue Biopharma’s Immuno-STAT platform underpins its product development approach, enabling targeted immune modulation across immunological disorders. Based in Boston, Massachusetts, Cue Biopharma participates in the biotechnology sector through a pipeline aimed at addressing unmet medical needs in allergy, inflammation, and autoimmunity.
Website40 Guest Street
Boston, MA, 02135
United States
The latest articles about CUE.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about CUE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.